BLAU3.SA
Strong BuyUnloved QualityAI neutralBlau Farmacêutica S.A. · Healthcare · Brazil · $459M
BRL 11.68 +7.9% · close 5 Oct · scored 3 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Blau Farmacêutica is a Brazilian maker of hospital-use injectable drugs and biologics, and it continues to pay regular interest-on-capital distributions. The valuation is reasonable, but pricing is heavily influenced by Brazilian public procurement and regulation, and there is little evidence of a durable competitive edge or accelerating growth.
ABOUT BLAU FARMACÊUTICA S.A.
Read
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4B | 1.4B | 1.8B | 1.7B | 6.6% | 1.8B | 1.9B | 2.2B | 13.5% |
| EPS (BRL) | 1.57 | 1.08 | 0.94 | 1.28 | -6.6% | 1.01 | 1.41 | 1.74 | 16.5% |
| Shares | 231.2M | 231.0M | 231.0M | 300.3M | +29.9% | 231.0M | — | — | — |
| Debt | 311.7M | 608.5M | 559.0M | 599.1M | 24.3% | 853.1M | — | — | — |
| Equity | 1.8B | 2.0B | 2.2B | 2.3B | 7.6% | — | — | — | — |
| Op CF | 171.9M | 220.6M | 507.2M | 290.8M | 19.2% | 424.4M | — | — | — |
| Inv CF | 133.0M | -356.8M | -314.7M | -154.7M | — | — | — | — | — |
| Fin CF | -342.6M | 153.6M | -190.7M | -120.3M | — | — | — | — | — |
Swung more than 66% of stocks we rank over the past year (52% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLAU3.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLAU3.SA | Blau Farmacêutica S.A.(you) | $459M | 85 | Strong Buy |
| OFSA3.SA | Ouro Fino Saúde Animal Participações S.A. | $268M | 98 | Strong Buy |
| HYPE3.SA | Hypera S.A. | $3.3B | 97 | Strong Buy |
| PGMN3.SA | Empreendimentos Pague Menos S.A. | $522M | 82 | Strong Buy |
| PNVL3.SA | Dimed S.A. Distribuidora de Medicamentos | $378M | 97 | Strong Buy |
| MATD3.SA | Hospital Mater Dei S.A. | $323M | 95 | Strong Buy |
| DASA3.SA | Diagnósticos da América S.A. | $782M | 74 | Buy |
| PFRM3.SA | Profarma Distribuidora de Produtos Farmacêuticos S.A. | $176M | 98 | Strong Buy |
| QUAL3.SA | Qualicorp Consultoria e Corretora de Seguros S.A. | $89M | 89 | Strong Buy |
| FLRY3.SA | Fleury S.A. | $2.3B | 99 | Strong Buy |
Peer medians: ROE 10.6% · P/E 14.2x · Gross margin 30.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.